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S U M M A R Y
The novel inﬂuenza A (H7N9) virus can cause severe illness, including pneumonia and acute respiratory
disorder syndrome (ARDS), with high rates of intensive care unit admission and death. We report the ﬁrst
case of human infection with avian inﬂuenza A (H7N9) virus in Shenzhen, China. The patient was a 38-
year-old man. His infection was eventually conﬁrmed 9 days after illness onset. No symptom was found
in his 135 close contacts. The patient recovered 43 days after illness onset. Oseltamivir, anti-infective
drugs, methylprednisolone, albumin, and intravenous immunoglobulin were administered. Antiviral
therapy in the early stage and sufﬁcient supportive management are key to the treatment of infections
with this virus, and proper doses of methylprednisolone and intravenous immunoglobulin are
recommended.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The ﬁrst three cases of avian inﬂuenza A (H7N9) virus infection
were reported in different locations across the Yangtze delta region
of eastern China in March and April 2013.1 Global attention was
soon focused on the situation due to the appearance of more and
more new cases and the high mortality associated with these
infections.
On December 12, 2013, a 38-year-old male worker presented
with a high fever and cough, which was later complicated by
severe pneumonia and respiratory failure (type I). He was
conﬁrmed to have an inﬂuenza A (H7N9) virus infection 9 days
later and was transferred to the Third People’s Hospital of
Shenzhen (an infectious disease hospital). The clinical and
epidemiological characteristics of this case and response measures
are reported below.
2. Case report
2.1. Data source
The epidemiological case survey was carried out on the basis of
the Prevention and control protocol for human infections with avian* Corresponding author.
E-mail address: 123rong@sohu.com (Y.-r. Wang).
http://dx.doi.org/10.1016/j.ijid.2014.05.007
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).inﬂuenza A (H7N9), 1st edition, of the National Health and Family
Planning Commission (NHFPC) of the People’s Republic of China.
Tracing of the infection sources and observation of the patient’s
close contacts were also conducted. The patient’s household was
disinfected. We collected information about recent exposures to
poultry and other animals, and other relevant epidemiological
information. The related clinical information was also collected.
2.2. Identiﬁcation and follow-up of close contacts
Once the close contacts had been identiﬁed, they were
monitored daily for 7 days for the presence of symptoms of
illness. Throat swabs were collected from contacts in whom
symptoms developed to test for the presence of the H7N9 virus.
3. Results
3.1. Clinical information
On December 9, 2013, the patient had fever, chills, and an
intermittent cough, with whitish-yellow sputum. He went to see a
doctor in the outpatient department of a primary hospital in
Shenzhen on December 12 and was admitted for pneumonia. He
had no other medical problems in his past history. Examination
revealed a maximum body temperature of 39.5 8C, white blood cell
count of 3.48  109/l, neutrophils% of 76.1%, potassium of 2.83
mmol/l, sodium of 133 mmol/l, creatine kinase of 3319 U/l,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Table 1
Clinical course of the ﬁrst case with H7N9 in Shenzhen, China.
Course Date Clinical information
Day 1 09 December, 2013 Fever, cough with whitish yellow sputum
Day 4 12 December, 2013 Admitted in Nanwan People’s Hospital, felt
short of breath, inﬂammation of the lower
lobe of the left lung and the upper lobe of
the right lung
Day 5 13 December, 2013 Admitted in ICU of Shenzhen People’s
Hospital, type I respiratory failure,
administered (imipenem, un-invasive
mechanical ventilation
Day 6 14 December, 2013 Administered oseltamivir
Day 7 15 December, 2013 Administered with MP
Day 8 16 December, 2013 Invasive mechanical ventilation,
administered IVIG
Day 10 18 December, 2013 Identiﬁed with H7N9(+), light coma, ARDS,
MODS, transferred to Third People’s
Hospital
Day 12 20 December, 2013 MDR-AB was identiﬁed both in blood and
sputum, administered with polymyxin
Day 14 21 December, 2013 No fever and coma
Day 16 23 December, 2013 Mediastinal emphesem, extubate, mask
oxygen inhalation
Day 19 26 December, 2013 Nasal catheter oxygen inhalation
Day 21 28 December, 2013 Drug allergy, diffuse rashes
Day 23 30 December, 2013 Phlebothrombosis of lower extremity
Day 27 03 January, 2014 Haematoma in right iliac fossa
Day 35 11 January, 2014 Discharged from ICU
Day 41 17 January, 2014 Avascular necrosis of the femoral head
Day 43 19 January, 2014 Discharge from hospital
IVIG, intravenous immunoglobulin; ARDS, acute respiratory disorder syndrome;
MODS, multi-organ dysfunction syndrome; MP, methyl-prednisone.
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alanine aminotransferase of 136 U/l, aspartate aminotransferase of
470 U/l, and albumin of 12.1 27 g/l. A chest X-ray showed infection
of the lower lobe of the left lung and the upper lobe of the right
lung. He felt shortness of breath and was transferred to the
Emergency Department of Shenzhen People’s Hospital on the
evening of December 13; he was diagnosed with severe pneumo-
nia, type I respiratory failure. After hospitalization, he was
transferred to the intensive care unit and was given integrated
management including antibiotic therapy, gastric protective
treatments, intravenous immunoglobulin (IVIG; 7.5 g/day), meth-
ylprednisolone (40 mg/day), and ﬂuid infusion. Oseltamivir was
administered over the following days. Invasive mechanical
ventilation was performed on December 16. The patient’s sputum
was sent to Shenzhen Center for Disease Control and Prevention
(CDC) for nucleic acid testing, and was positive for inﬂuenza A
(H7N9). He was eventually conﬁrmed to have an inﬂuenza A
(H7N9) infection and was transferred to the Third People’ Hospital
of Shenzhen (an infectious disease hospital) on December 18. A
chest X-ray was taken 3 days after illness onset. The results are
shown in Figure 1. Mechanical ventilation was stopped 14 days
later. He recovered after experiencing sepsis, adult respiratory
disorder syndrome (ARDS), mediastinal emphysema, a drug
allergy, and phlebothrombosis of the lower extremity. Multi-
drug-resistant Acinetobacter baumannii (MDR-AB) was identiﬁed in
both his blood and sputum. Our conventional antibiotics were not
found to be effective. Polymyxin was administered promptly. He
eventually recovered. Table 1 shows the main clinical course. He
was discharged on January 19, 2014.
3.2. Epidemiological information
The patient was a blue-collar worker in an electronics factory in
Shenzhen City, Guangdong Province. He had bought chickens at a
farm produce market and had eaten the meat prior to the onset of
disease on November 20, 2013. He denied raising and killing live
poultry recently. He had not had contact with fever patients or
similar patients before disease onset.
One hundred and thirty-ﬁve close contacts were identiﬁed
(people living near the patient, working with the patient, and those
admitted to the same hospital), including three patients sharing aFigure 1. Chest X-ray ﬁlm of the patient with pneumonia caused by avian inﬂuenza
A (H7N9) virus taken 3 days after illness onset.ward, 15 family members and relatives, 100 colleagues, and 17
healthcare providers without protected contact. The close contacts
were followed for at least 7 days. Throat swabs were collected from
seven close contacts in the factory and all tested negative for H7N9
virus nucleic acid.
3.3. Treatment and prevention management
To ensure that the correct protocol for avian inﬂuenza A (H7N9)
patients was followed, an emergency panel was established in
Shenzhen. The patient was treated with oseltamivir, antimicrobial
drugs, IVIG, and steroids to suppress lung inﬂammation, and
invasive mechanical ventilation was implemented. Terminal
disinfection was established in the places involved in the diagnosis
and management processes.
4. Discussion
Human infections with the novel inﬂuenza A (H7N9) virus were
ﬁrst identiﬁed in China in March 2013; the initial laboratory-
conﬁrmed cases were all patients with serious illness.2 There have
been sporadic reports indicating that human infections with
inﬂuenza A (H7) viruses are usually associated with exposure to
poultry.3 The closure of live poultry markets appears to have been
effective in the control of outbreaks.4 Our patient had had direct
contact with poultry prior to the onset of the disease. So
suspending farmers markets with live birds and stopping the
transport of live birds could prevent new human infections.
Follow-up prospective surveys of close contacts of patients with
identiﬁed H7N9 virus infections have not conclusively conﬁrmed
human-to-human H7N9 transmission from one infected case to
another. Some people hold the opinion that in family clusters,
limited human-to-human transmission of H7N9 virus after close,
unprotected, prolonged contact with a suspected patient with
H7N9 virus infection is possible. Limited human-to-human H5N1
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necessary to isolate patients promptly, follow up close contacts
actively, and for health care personnel to carry out standard
precautions in hospitals.
Neuraminidase inhibitors (e.g., oseltamivir) are the available
drug treatment for inﬂuenza A (H7N9) virus infection but there is
controversy regarding the beneﬁts of oseltamivir treatment of
inﬂuenza A (H7N9) virus infections. We conclude that antiviral
therapy in the early stage and sufﬁcient supportive management
are key to the treatment of infections with this virus, and proper
doses of methylprednisolone and IVIG are recommended.
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